univers coverag
calendar event
multi-national associ support cancer intern societi oral
bottom line tuesday host day nyc medacorp physician across
number key med-tech specialti assess market growth dynam outlook well
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
key technolog drive growth share shift within specialti provid high-
level takeaway discuss seven physician cover rang topic continu insid
note detail takeaway includ in-depth discuss specialist servic line
market penetr prospect view new emerg technolog
mani topic compani discuss call select area margin
increment less bullish stock coverag univers would includ
intervent cardiolog discuss reinforc view slower steadier move
risk curv posit commentari impella
neurovascular surgeri imag may battleground portfolio differenti rise
spine surgeri robot player share gain potenti otherwis still challeng end-
electrophysiolog earli sign bundl effort impact share shift atrial fibril ablat volum
growth strong capac constrain conserv ep view watchman use
thorac surgeri robot adopt curv appear steepen could provid sustain
procedur growth momentum futur
spinal cord stimul bullish posit outcom drive share practic
get pharmaci near term threat modest
bottom line host call medacorp specialist thursday discuss acquisit
pillpack implic pharmaci suppli chain drug distribut perspect
believ pose long-term threat retail pharmaci howev surpris hear
specialist state expect captur retail market share
believ drug distributor displac pillpack modest market share
right mail volum declin pbm could choos exclud
network pbm distributor trade near year trough multipl believ sell-
suppli chain overdon
pillpack modest market share
sponsor want exclud pillpack network
prime eas order could drive growth pillpack
believ distributor expos retail
long-term risk
 pillpack muse deal
bottom line see deal pillpack clear threat retail drug store chain
medium term drug wholesal though view like
partner esrx mp optum rx build buy pbm reiter view
manag threat move given clear trend toward integr pbm
across data enabl clinic care pharmaci benefit manag capabl bridg far
see weak strong buy opportun particularli op op
op wcg op op see like ink partnership come
month like reason pass pillpack
pillpack deal signal intent enter on-line prescript drug fulfil market view
expect could offer low cost gener back mm prime consum platform
gener prescript drug market
threat retail drug store chain op mp rite aid/albertson etc
like threat medium term drug wholesal mp op mp
backward integr drug wholes expect possibl
think like partner exist pbm build buy pbm
base view healthcar servic landscap expect tabl
pillpack consumm deal like discuss possibl
deeper relationship encompass co-brand prescript drug part product state
art mail order capabl
dbg focus futur integr deliveri
ep
bottom line reiter outperform rate pt offer insight
antm recent creat diversifi busi group dbg ceo gail boudreaux context
leadership chang presid prakash patel recent convers
compani newli form dbg mini-optum within anchor specialti benefit
manag aim specialti health tech-en palli care provid aspir health integr plan/
deliveri network caremor health dbg critic antm futur success integr care deliveri
leadership deepli focus achiev connect across touch point build
block determin next move capit deploy posit potenti
leadership manag administr cost achiev high level technolog integr
develop platform gener third parti revenu eventu serv util
newli form diversifi busi group dbg leadership ceo gail
boudreaux new presid prakash patel build platform integr care deliveri
key pillar aim caremor build flagship captiv pbm ingeniorx
aim specialti health evolv radiolog benefit manag rbm acquir wlp/antm
full servic specialti benefit divis dbg
aspir health palli care provid recent acquir dbg
caremor health antm integr health plan deliveri system reli high-touch care model
includ extensivist neighborhood care center like area futur integr
kol discuss head neck cancer landscap tipifarnib
dcf analysi revenu multipl dr tgr
bottom line clinical-stag biotechnolog compani develop precis medicin
oncolog view lead pipelin program tipifarnib farnesyltransferas inhibitor activ
drug manag safeti profil view well-posit long-term manag
team execut well tipifarnib develop strategi recal licens world-wide
right tipifarnib indic virolog janssen op previous evalu
tipifarnib broadli across variou hematolog solid tumor limit success believ
precis medicin approach develop tipifarnib biomarker-defin patient offer opportun
improv past effort base review literatur medacorp kol check excit
initi data gener hra mutant hrasm squamou cell carcinoma head
neck scchn still concern investor data gener
small number patient develop headwind includ adopt routin genet
screen scchn implic develop path forward ahead initi
registration-direct tipifarnib scchn studi aim-hn spoke two medacorp kol
highlight view scchn landscap opportun tipifarnib describ within
registration-direct tipifarnib hrasm scchn studi aim-hn track initi
takeaway kol convers
ep
bottom line attend annual analyst day boston manag re-affirmed
guidanc guid consensu prior estim overal compani
commentari around price posit manag seem focus drive growth
specialti deepen manufactur relationship well take cost back-offic
function day present overshadow news manag
downplay cite scale long-term relationship follow present remain
neutral stock confid visibl result off-set risk around renew
price unfavor sentiment due regulatori risk tweak estim
reflect guid remain mp rate share price target
headwind europ fought ad custom valu
comment posit
adjust estim reflect stronger guid
adjust ep exclud acquisit relat cost acquisit relat amort non-recur item
includ awp reserv lifo adjust
gatan acq complement fei electron microscopi strengthen market
bottom line close announc intent acquir gatan inc roper
technolog cash sale compar multipl
trail revenu paid fei expect acquisit highli complementari
fei acquisit believ strengthen posit electron microscopi
em space transact expect close end integr
gatan product highli complimentari fei best class come electron microscopi
em holder ccd camera softwar need mani experi
gatan acquisit add fei analyt instrument segment
complementari product portfolio integr fei allow addit upsid
may lever given free cash flow
never toss albatross cheer pelican
ep rev disc dcf wacc tg
bottom line afternoon galapago announc disappoint result pelican
phase ii trial proprietari second-gen cftr corrector homozyg
cystic fibrosi cf patient tripl increas top orkambi vs placebo
materi lower benefit within group offer three vertex second-
gen corrector top symdeko result even lower mid high singl digit increment
effect anticip rais question viabil molecul glpg
overal develop strategi cf glpg disclos achiev mmol/l reduct
sweat chlorid also materi lower reduct sweat chlorid shown vertex
tripl combin concurr announc abbv/mp opt
futur develop second galapago tripl combin result two compani
review futur cf collabor none particularli surpris us
consist forecast valuat view vertex stock howev remind
follow recent pti op result offer similar insight difficulti complex
multi-compound drug develop project high wall around vertex futur valu cf
look easi discov test develop three four differ molecul specif
diseas simultan doesnt mean realli easi fact histor difficulti endeavor
increas exponenti number compound involv particularli requir
effect co-formul co-administ vertex accomplish task sever time
result investor come fear competitor abl well thu vertex stock
suffer smooth execut howev two recent competit disappoint
investor like recogn inher challeng program expect restor much
vertex recent valu still probabl success glpg doublet
triplet cf market model underpin recent target price vertex
inform becom avail glpg result separ seem like
probabl success go thu perceiv valu vertex market revenu
earn cash flow stock price go believ glpg still long road ahead
develop cf see note glpg great molecul drug
us surpris see disclosur intent partner go separ way
volum driven on-board us margin remain pressur pt
 methodolog ep
bottom line decent quarter view publish updat model
account result updat guidanc quarter overal ok believ
deliv anoth quarter low qualiti earn quarter adj ep beat consensu
estim driven lower tax rate provid benefit lower-end
guidanc rais estim reflect lower-than expect tax rate
quarter us retail result bolster addit store margin
remain pressur due higher mix specialti possibl mix store
intern retail result mix divis oper incom miss estim
wholesal result beat estim seem highli focus market share rx volum
growth despit rx fill comp store flat y/i agre volum import howev
continu believ reduc rate plan pbm order gain share result
gross margin percentag revenu usa retail remain pressur maintain mp
pt decreas
integr on-track bolster us retail divis top-lin margin disappoint
hub model pilot continu evolv seek deliv true omni channel experi
low-end guidanc increas
ep exclud acquisition-rel cost acquisition-rel amort non-recur item includ lifo
adjust revenu billion
bottom line today host med-tech leadership seri call ceo scott wilkinson
cfo ali bauerlein tone call upbeat -- terribl surpris given recent trajectori
stock compani result deliv strongest quarterli beat to-dat
point leav call feel increment posit key point
mind could justifi recent stock strength -- importantli -- bode well
continu sale out-performance forese futur larg signific
runway still -- manag believ poc portabl oxygen concentr penetr reach
penetr total oxygen therapi market within next year vs today
may fare better light increas competit risk fear given meaning
differenti poc reliabl perspect seemingli import hme
home medic equip provid appreci remain
heavi invest mode sale market near-term compani see posit leverag
 help off-set long-term expect abl drive increment leverag sale
market well
acquir pillpack remain interest drug channel
bottom line announc acquisit tech-en pharmaci pillpack show
continu interest drug channel transact expect close term
yet announc
offici pharmaci suppli chain pillpack
bottom line amazon offici enter pharmaci market acquisit
pillpack privat announc morn pillpack late stage on-line pharmaci start-up
base somervil term disclos deal expect close
previou press report april said talk purchas on-line pharmaci
compani use technolog simplifi user experi like made
attract target good fit expect share tradit retail pharmaci
op mp esrx mp weak today news market view
recent believ delay plan enter pharmaci market least
temporarili shelv plan enter hospit distribut space
name prakash patel md presid diversifi busi group
bottom line op name prakash patel execut vice presid presid
diversifi busi group dbg dbg includ pillar antm integr care deliveri
platform aim specialti health caremor health aspir health among other dr patel
current chief oper offic guidewel enterpris florida previous serv
ceo access mediquip held senior execut role op internet
healthcar group familiar high regard dr patel tenur
florida current dbg presid evp chief clinic offic dr
craig samitt becom presid ceo cross shield minnesota
potenti promis exon skipper emerg near-term threat
bottom line ns pharma present data exon skip drug
specif two separ trial japan us/canada show dystrophin express level
normal higher seen sarepta golodirsen link link howev
reach agreement fda nda file experienc commerci
salesforc rapidli advanc potenti revolutionari gene therapi link sarepta
duchenn muscular dystrophi dmd franchis appear well-insul view reiter op
management outlin path out-performance lt strateg prioriti
averag dcf price-to-earnings
analyst day reinforc view dd growth sustain longer-
sale
sell medicaid mi busi
catalyst could derisk platform
outperform market cap price price target methodolog dcf
discount rate termin growth rate
next import catalyst alder six month data ph pivot trial
chronic migrain due second quarter american headach
trial expect provid extend durat repeat dose safeti efficaci
month
data expect includ bla eptinezumab need
consist earlier announc data free increas new
advers event increas neutral antibodi
pr medicaid manag care contract triple- first medic
incumb expect announc late june earli juli
within coverag incumb market share total
incumb triple- first medic
market share respect enrol popul elig
request propos rfp receiv respons includ respons
incumb op within coverag
gener premium revenu estim oper loss
puerto rico lower averag pmpm
new contract anticip go-liv octob dictat
puerto rico move oper model mco must provid coverag
across territori one region
upcom catalyst risk adjust data juli earn
tx award octob
announc final patient dravet studi complet dose
may expect report top-lin data trial late june earli juli
dravet syndrom present signific unmet medic need compel clinic
data first two dravet studi render investor physician
patient excit potenti drug
initi phase studi demonstr unpreced level seizur
reduct dravet patient
initi roll nda base result two phase dravet
studi data avail open-label extens suffici
patient exposur support safeti requir file
earlier may report on-going phase iib studi rti elderli
complet dose final patient put trial track top-lin data readout
binari name within coverag univers anticip tremend
volatil around report phase iib top-lin data
believ current impli probability-of-success po studi offer
attract invest opportun investor will accept risk inher
project ww pos-adjust revenu rti /-
believ investor expect head ph data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
one regn import catalyst approv antibodi cemiplimab
cutan squamou cell carcinoma cscc
compani pdufa date octob research suggest first approv
checkpoint antibodi new indic typic come ahead pdufa date like
june juli cemiplimab estim
particularli true applic benefit breakthrough design
prioriti review case cemiplimab
regeneron also appear signal expect approv occur earlier
date confirm us commerci team readi launch product
immedi avail channel
project peak pos-adjust us cemiplimab sale
note ph criteria differ nccn guidelin meant trial
result directli compar prior studi
discuss fda on-going primari endpoint determin
told endpoint may similar select ph design
link note
recent pamrevlumab result suggest convent ct scan may accur predict
resect lapc patient
success pamrevlumab neoadjuv set may depend chang resctabl
standard adopt clinic regulatori commerci endpoint
late august omadacyclin antibiot skin pneumonia adcom
key catalyst remain time-frame conven adcom potenti
aug time-frame potenti approv oct time-frame could move
view fda decis panel indic concern
link view panel public forum review posit risk/
benefit profil omadacyclin evidenc last nce antibiot pneumonia
sinc adcom conven
continu view data packag omadacyclin support approv
believ current level street underappreci valu omadacyclin
gain clariti key discuss topic brief document
releas publicli two busi day ahead adcom date
pdufa date expect octob
augment trial approach complet top-lin result releas
trial studi cytotoxic-fre combin revlimid rituximab
would attract altern cytotox standard-of-car fl
degre upsid limit time like approv adopt
reimburs indic expect generic revlimid
believ data present american psychiatr associ confer
provid limit insight genesight endpoint
view test key mygn long-term top-lin growth potenti
drive revenu upsid reimburs mygn desir
current medicar rate
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons data may provid sub
analysi patient fail chang view medacorp specialist payer
journal public expect june coverage/contract decis expect
announc beyond
link takeaway meet manag
sourc leerink research compani inform factset price prior day
pdufa derm hyperhidrosi excess sweat link impact
medcac panel procedur volum requir hospit heart team
member begin maintain transcathet aortic valv replac
medcac panel t-cell therapi
pdufa teva fremanezumab cgrp migrain
fda adcom vaccin relat biolog product
pdufa dupix moder sever asthma adult adolesc
pdufa xyrem cataplexi excess daytim sleepi
pdufa revefanacin lama copd
pdufa bremelanotid hypoact sexual desir disord fda adcom
schedul
multi-national associ support cancer intern societi
american orthopaed societi sport medicin
american societi virolog
american societi healthcar engin
societi studi ingest behavior
intern societi thrombosi haemostasi
breast surgeri bodi contour symposium
american societi retina specialist
societi neurointervent surgeri
go live az
model recent updat pleas contact leerink repres
wish review
 highlight kol panel lung cancer io cell
 rova-t present show anoth rout failur experiment oncolog
adap -- flash manag convers highlight data pipelin progress
adap studi advanc cell dose posit safeti data pt
-- flash present highlight opportun colorect cancer
celg updat strengthen profil remark respons durabl
celg profil continu present outperform
 tazemetostat mesothelioma data opportun combin outperform
 success pamrevlumab lapc may depend endpoint paradigm shift
imdz -- flash event highlight imdz approach strategi outperform
 event highlight investig view forward ii data outperform
-- flash highlight encourag data biomark strategi gastric
-- flash updat demonstr continu safeti earli efficaci
-- flash aducanumab phase trial expand variabl endpt requir
 growth margin management stabil still lack pipelin catalyst market
 ctad medacorp call aducanumab abeta hypothesi
 state larg cap biotech sfo steadi goe
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 growth deal capac target market
biopharma praluent show mortal benefit lower take aim highest risk group
mdco -- flash inclisiran lesson fourier/odyssey may better
novob dc highlight nvo management roundtabl discuss boston market
medic devic leerink healthcar confer panel devic penetr set
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
medic devic leerink healthcar confer panel devic penetr set
medic suppli devic initi takeaway sage robot continu gain
medic devic survey support market share re-gain assumpt
medic devices-cardiolog hr takeaway cabana unlik chang af practic
biopharma price right payer fail get drug class come
 stabil sell-sid price trend medic posit ug op outperform
hcit distribut fda take step improv competit distributor near trough
 acthar survey suggest faster eros payer pressur competitor entri
qure updat model higher price assumpt po pt
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
biopharma trump-azar puls call drug price blueprint limit current hh
 hemophilia price adjust reflect efficaci luxturna paradigm pt
 outlook move higher price clariti suggest possibl upsid pt
hcit distribut blueprint thorough pbm like abl manag rebat
hcit distribut outlin possibl drug price polici draconian
fear
 updat hemophilia price assumpt ad pomp program pt
adap kol address controversi ahead multipl data readout outperform
 anoth setback ido outperform ideal combo still unclear
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
biopharma -- flash highlight io combin seri puls call front-lin lung
biopharma highlight io agonist checkpoint puls call updat
celg anoth bet car-t probabl probabl sensibl even
 deep dive highlight oncolog focu strategi nash market perform
celg anoth bet car-t probabl probabl sensibl even
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
biopharma cafc oral argument justic challeng scope ab patent
 patent issuanc reflect execut strategi pt outperform
 investor sleep path ip protect pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
hcit distribut -- flash minut stori appear one-sid
achn partnership termin push cfd inhibitor main stage pt
athn survey highlight slow market time take deal pt market
biopharma might deton event look like screen pot match-
 sotp support current stock price where pipelin upsid market
 sotp suggest pipelin free even stock bounc market perform
biopharma viii partnership acquisit biopharma new top list
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 dupi miss-inventori demand trend intact partnership flail
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
 initi adama step forward parkinson dyskinesia outperform
deal capac
moat vs
 insight april nyc hc servic day convict
 mylan upgrad valuat disconnect given diversifi busi catalyst
path outperform
 initi could adenosin inhibit unlock wave i/o
outperform
 come-back stori make survey support opu market
share assumpt outperform
 initi doubl digit growth meaning margin expans ahead
outperform
-- contact leerink repres detail access podcast
 pnh survey-soliri still grow like switch monthli sc best
athn survey highlight slow market time take deal pt market
biopharma atop derm still without ped leerink dupi derm survey
 hiv survey rapid adopt biktarvi challeng outlook
hcit distribut ambulatori survey show slowdown replac market on-going
shift vbc
hcit distribut demand shift analyt effect use
 vyxeo survey suggest outpati usag grow outperform
major medacorp survey lung cancer posit azn
limit upsid link
medic suppli devic survey flu help otherwis normal volume downtick
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
medic devic survey direct posit mute hope
teva rais austedo sale analysi posit medacorp physician survey
 ceo call focus growth outlook potenti upsid area lrp pt
outlook alpha opportun abound healthcar share
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
